tiprankstipranks
Trending News
More News >
Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
Australian Market

Lumos Diagnostics Holdings Ltd. (LDX) AI Stock Analysis

Compare
10 Followers

Top Page

AU

Lumos Diagnostics Holdings Ltd.

(Sydney:LDX)

Rating:47Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Lumos Diagnostics receives a score of 47, primarily due to its financial struggles, including negative profitability and high leverage. Technical analysis indicates overbought conditions, suggesting potential price volatility. The negative P/E ratio highlights valuation concerns. While there are positive signs in gross margins and cash flow, the company must focus on financial stability and profitability.

Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)

Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model

Company DescriptionLumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
How the Company Makes MoneyLumos Diagnostics generates revenue primarily through the sale of its diagnostic products and services. The company's revenue streams include direct sales of point-of-care diagnostic tests to healthcare providers, laboratories, and other medical institutions. Additionally, Lumos collaborates with partners and distributors to expand its market reach, which also contributes to its earnings. The company may also engage in strategic partnerships or licensing agreements to leverage its proprietary technology, further enhancing its revenue potential. Factors such as regulatory approvals, market demand for rapid diagnostics, and technological advancements significantly influence Lumos Diagnostics' earnings.

Lumos Diagnostics Holdings Ltd. Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
11.13M10.54M11.63M18.85M5.79M
Gross Profit
7.10M5.97M4.46M8.60M2.51M
EBIT
-5.01M-10.24M-21.49M-11.00M-10.72M
EBITDA
-5.44M-4.93M-18.67M-10.69M-10.41M
Net Income Common Stockholders
-8.59M-8.97M-45.72M-15.03M-9.28M
Balance SheetCash, Cash Equivalents and Short-Term Investments
6.48M3.02M7.98M44.89M850.93K
Total Assets
26.84M25.42M36.94M97.99M30.28M
Total Debt
8.06M9.79M7.19M7.20M3.24M
Net Debt
1.58M6.77M-784.00K-37.69M2.39M
Total Liabilities
19.73M15.92M19.05M39.71M8.12M
Stockholders Equity
7.11M9.50M17.89M58.28M22.16M
Cash FlowFree Cash Flow
848.00K-9.79M-22.39M-16.77M-10.28M
Operating Cash Flow
946.00K-9.64M-18.04M-10.89M-3.76M
Investing Cash Flow
-98.00K4.31M-4.36M-8.33M-6.52M
Financing Cash Flow
2.63M652.00K-10.92M63.27M8.12M

Lumos Diagnostics Holdings Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.03
Price Trends
50DMA
0.03
Positive
100DMA
0.03
Positive
200DMA
0.03
Negative
Market Momentum
MACD
<0.01
Positive
RSI
90.35
Negative
STOCH
71.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:LDX, the sentiment is Positive. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 90.35 is Negative, neither overbought nor oversold. The STOCH value of 71.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:LDX.

Lumos Diagnostics Holdings Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
AULDX
47
Neutral
AU$23.20M-51.49%80.84%57.59%
$25.01M-75.39%
$256.80M-31.16%
AURAC
54
Neutral
AU$205.88M-37.20%32.02%
AUAT1
39
Underperform
AU$10.98M-61.15%35.63%18.55%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.03
0.00
0.00%
CYYNF
Cynata Therapeutics Limited
0.12
<0.01
9.09%
PRRUF
Immutep Ltd
0.19
-0.09
-32.14%
AU:RAC
Race Oncology Ltd.
1.18
-0.72
-37.89%
AU:AT1
Atomo Diagnostics Ltd.
0.02
>-0.01
-33.33%

Lumos Diagnostics Holdings Ltd. Corporate Events

Lumos Diagnostics Announces Change of Business Address
Jun 2, 2025

Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a change in its registered office and principal place of business to a new address in Melbourne, Australia. This move is part of the company’s ongoing efforts to streamline its operations and enhance its market presence, with all other contact details remaining unchanged.

Lumos Diagnostics Expands Medicare Coverage for FebriDx®
May 26, 2025

Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx® test from a sixth Medicare Administrative Contractor (MAC), CGS Administrators, which covers Kentucky and Ohio. This achievement means Lumos now has reimbursement coverage from six out of seven MACs, representing over 85% of US Medicare payment coverage, significantly expanding its access to the Medicare patient population. This development is a critical milestone for Lumos, as Medicare often sets a precedent for private insurance payors, and it demonstrates the company’s commitment to achieving nationwide access and broad clinical adoption of FebriDx.

Lumos Diagnostics Expands Medicare Coverage for FebriDx Test
May 19, 2025

Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx test from a fifth Medicare Administrative Contractor (MAC), WPS Health Solutions, retroactive from May 1, 2025. This achievement means Lumos now has coverage from five of the seven MACs, covering over 70% of US Medicare payments, which significantly enhances its access to the Medicare patient population. The company is actively negotiating with the remaining two MACs and aims to secure reimbursement from private insurers, striving for nationwide access and broad clinical adoption of FebriDx.

Lumos Diagnostics Secures Major FebriDx Order from iMedical
May 13, 2025

Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a significant purchase order for its FebriDx test from iMedical, Inc., marking the largest single order since the test’s launch. This order underscores the growing acceptance and demand for FebriDx in the US market, following its FDA clearance in July 2023 for aiding in the diagnosis of bacterial acute respiratory infections. The collaboration with iMedical, a company known for providing cost-saving solutions to healthcare facilities, is expected to enhance the market presence of FebriDx and improve health outcomes through advanced point-of-care technology.

Lumos Diagnostics Issues 23 Million Performance Rights
May 9, 2025

Lumos Diagnostics Holdings Ltd. announced the issuance of 23,000,000 unquoted performance rights as part of an employee incentive scheme. This move is aimed at enhancing employee motivation and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning positively.

Lumos Diagnostics Releases Q3 FY25 Investor Briefing
May 6, 2025

Lumos Diagnostics Holdings Ltd. has released an investor briefing for Q3 FY25, emphasizing that the information is solely for informational purposes and not intended as a basis for investment decisions. The document highlights the company’s focus on providing diagnostic solutions, but it also includes disclaimers regarding the accuracy and reliability of the information, emphasizing the inherent risks and uncertainties in market data and forecasts.

Lumos Diagnostics Reports Strong Q3 FY25 Revenue Growth and Strategic Advances
Apr 29, 2025

Lumos Diagnostics reported a revenue of US$3.5 million for the third quarter of FY25, marking a 21% increase from the previous quarter, although down 13% from the same period last year. The company saw significant growth in its services and product revenues, with notable developments including new distribution partnerships for FebriDx® in the U.S. and the expansion of the Hologic fFN project. The company also achieved successful audit results for its quality management system, and FebriDx® was added to the Medicare Fee Schedule, potentially enhancing its market reach.

Lumos Diagnostics Expands Medicare Coverage for FebriDx®
Apr 23, 2025

Lumos Diagnostics has secured additional U.S. Medicare reimbursement coverage for its FebriDx® test from two more Medicare Administrative Contractors (MACs), First Coast Service Options and Noridian Healthcare Solutions. This achievement expands Lumos’ Medicare coverage to four out of seven MACs, covering over 55% of U.S. Medicare payments. This milestone is crucial for the commercial success of FebriDx, as Medicare adoption often influences private insurance payors’ decisions. Lumos continues to pursue coverage from the remaining MACs and private payors to achieve nationwide access and support broad clinical adoption.

Lumos Diagnostics Secures Key U.S. Reimbursement Milestones for FebriDx®
Apr 17, 2025

Lumos Diagnostics has achieved significant milestones in securing U.S. reimbursement for its FebriDx® test, a rapid diagnostic tool for respiratory infections. The company has obtained reimbursement coverage with two Medicare Administration Contractors, setting a reimbursement rate of $41.38 per test effective April 2025, and is progressing negotiations with additional contractors. This development is expected to facilitate broader adoption by private insurers, enhancing FebriDx’s role in improving clinical outcomes and reducing unnecessary antibiotic prescriptions.

Lumos Diagnostics Hosts Investor Presentation in Sydney
Apr 2, 2025

Lumos Diagnostics Holdings Ltd, a leader in rapid point-of-care diagnostic technologies, is hosting an investor presentation in Sydney to provide insights into its operations and future strategies. This session aims to engage investors and stakeholders, highlighting Lumos’ commitment to advancing healthcare diagnostics and potentially impacting its market positioning and stakeholder interests.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.